drugset / Trial / NCT00290342

Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants

NCT00290342 ↗

Phase 3 Completed 458 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelPrevention

Summary

DTPa and IPV vaccines are recommended for immunization of infants in Korea. The use of combination vaccines simplifies routine paediatric vaccination. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Timeline

Start
2006-01-01
Primary completion
2007-01-01
Completion
2007-01-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator DTPa Vaccine — Intramuscular
Subject DTPa-IPV Vaccine — Intramuscular
Comparator IMOVAX Polio Vaccine — Intramuscular

Indications